Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura

Current Paediatrics

Volumn 12, Issue 7, 2002, Pages 569-574

  Karpman, Diana ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Factor H; Haemolytic uraemic syndrome; Paediatric; Shiga toxin; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BLEOMYCIN; CISPLATIN; CYCLOSPORIN A; DIAZEPAM; MITOMYCIN C; PHENYTOIN; QUININE; SHIGA TOXIN; SPASMOLYTIC AGENT; TACROLIMUS;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; AUTOIMMUNE DISEASE; BLOOD FLOW; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INDICATION; EPILEPSY; ESCHERICHIA COLI; FEVER; FLUID THERAPY; GENE MUTATION; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYDRATION; KIDNEY DISEASE; LABORATORY DIAGNOSIS; MICROANGIOPATHY; PARENTERAL NUTRITION; PATHOGENESIS; PATIENT MONITORING; PLASMA TRANSFUSION; PROGNOSIS; SHIGELLA DYSENTERIAE; STREPTOCOCCUS PNEUMONIAE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0036890775     PISSN: 09575839     EISSN: None     Source Type: Journal    
DOI: 10.1054/cupe.2002.0346     Document Type: Conference Paper

References (23)

1. Milford D V, Taylor C M. New insights into the haemolytic uraemic syndromes. Arch Dis Child 1990; 65: 713-715.
2. Lopez E L, Contrini M M, Devoto S et al. Incomplete hemolyticuremic syndrome in Argentinean children with bloody diarrhea. J Pediatr 1995; 127: 364-367.
3. Fitzpatrick M M, Walters M D, Trompeter R S, Dillon M J, Barratt T M. Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood. J Pediatr 1993; 122: 532-537.
4. Moake J L. Haemolytic-uraemic syndrome: Basic science. Lancet 1994; 343: 393-397.
5. Mead P S, Griffin P M. Escherichia coli OI57:H7. Lancet 1998; 352: 1207-1212.
6. McGraw M E, Lendon M, Stevens R F, Postlethwaite R J, Taylor C M. Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen. Pediatr Nephrol 1989; 3: 135-139.
7. Habib R. Pathology of the haemolytic uremic syndrome. In: Kaplan B S, Trompeter R S, Moake J L (eds). Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker Inc., 1992; 315-353.
8. Karmali M A, Petric M, Lim C, Fleming P C, Arbus G S, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-782.
9. Uchida H, Kiyokawa N, Horie H, Fujimoto J, Takeda T. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Pediatr Res 1999; 45: 133-137.
10. Prouix F, Seidman E G, Karpman D. Pathogenesis of Shiga toxinassociated hemolytic uremic syndrome. Pediatr Res 2001; 50: 163-171.
11. te Loo D M, Monnens L A, van Der Velden T J et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95: 3396-3402.
12. van de Kar N C, Monnens L A, Karmali M A, van Hinsbergh V W. Tumor necrosis factor and interleukin-I induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80: 2755-2764.
13. Chandler W L, Jelacic S, Boster D R et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32.
14. Karpman D, Papadopoulou D, Nilsson K, Sjogren AC, Mikaelsson C, Lethagen S. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-3108.
15. Zipfel P F. Hemolytic uremic syndrome: How do factor H mutants mediate endothelial damage? Trends Immunol 2001; 22: 345-348.
16. Furlan M, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
17. Levy G G, Nichols W C, Lian E C et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
18. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
19. Karpman D, Békássy Z D, Sjögren A-C et al. Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatr Nephrol 2002; 17: 201-211.
20. Wong C S, Jelacic S, Habeeb R L, Watkins S L, Tarr P I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli OI57:H7 infections. N Engl J Med 2000; 342: 1930-1936.
21. Takeda T, Yoshino K, Uchida H, Ikeda N, Tanimura M. Early use of fosfomycin for Shiga toxin-producing Escherichia coli infection reduces the risk of haemolytic-uremic syndrome. In: Kaper JB, O'Brien AD (eds). Escherichia Coli O157:H7 and Other Shiga Toxin Producing E. Coli Strains. Washington DC: ASM Press, 1998; 385-387.
22. Paton A W, Morona R, Paton J C. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000; 6: 265-270.
23. Kaplan BS, Leonard MB. Autosomal dominant hemolytic uremic syndrome: Variable phenotypes and transplant results. Pediatr Nephrol 2000; 14: 464-468.